Investors

OptiBiotix Health plc (“OptiBiotix”) notes the announcement made by ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, on 25 September 2024, that it has received a notice requisitioning a General Meeting (the “Requisition Notice”) which has been served by Platform Securities Nominees Limited, on behalf of Seneca Partners.

OptiBiotix is aware of the Requisition Notice and of the detailed reasons given by Seneca Partners for resorting to this course of action.

OptiBiotix intends to vote its holding of 53,533,333 ordinary shares in support of the resolutions proposed by Seneca Partners and will publish its full reasons for supporting the proposals put forward by Seneca Partners in due course.

In the meantime, OptiBiotix believes that it is important that ProBiotix Health plc clarify its issued share capital which is stated to be 158,166,666 shares carrying voting rights in its announcement of 4 September 2024 but is stated to be 121,666,666 shares carrying voting rights on its website at https://probiotixhealth-ir.com/share-information/shareholder-information.

Neil Davidson, Chairman of OptiBiotix Health plc said: “I am sure that Seneca Partners have only taken this action as an institutional shareholder after much careful consideration and for good reason. Shareholder activism led by institutional shareholders is an important aspect of corporate governance and should generally be seen as an indication that serious failings have been identified which need to be addressed in the best interests of all shareholders.”

About OptiBiotix www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.